Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Academic Article

Overview

abstract

Clinical Trials Registration: NCT02263326.

authors

Taiwo, Babafemi O

Marconi, Vincent C

Moser, Carlee B

Nyaku, Amesika N

Fichtenbaum, Carl J

Benson, Constance A

Wilkin, Timothy
Koletar, Susan L
Colasanti, Jonathan
Acosta, Edward P
Li, Jonathan Z
Sax, Paul E

publication date

May 17, 2018

published in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Journal

Research

keywords

Anti-HIV Agents
HIV Infections
HIV-1
Heterocyclic Compounds, 3-Ring
Lamivudine

Identity

PubMed Central ID

PMC5961309

Scopus Document Identifier

85047540507

Digital Object Identifier (DOI)

10.1093/cid/cix1131

PubMed ID

29293895

Additional Document Info

has global citation frequency

83

volume

66

issue

11